Spots Global Cancer Trial Database for Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Official Title: Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Study ID: NCT02779101

Conditions

Primary Central Nervous System Lymphoma

Interventions

pembrolizumab

Study Description

Brief Summary: In summary, there is a high medical need for patients suffering from recurrent/progressive PCNSL. Targeting the PD-1 pathway may represent a very promising novel approach for the treatment of these patients.

Detailed Description: The objective of this study are: PRIMARY OBJECTIVES * To evaluate the Overall Response Rate (CR/PR) in patients treated with pembrolizumab for relapsed PCNSL after MTX-based first-line therapy * To evaluate the safety of pembrolizumab in subjects diagnosed with recurrent PCNSL SECONDARY OBJECTIVES * To describe Best Overall Response categories (CR, PR, SD, PD) in patients treated with pembrolizumab for relapsed PCNSL after MTX-based first-line therapy * To describe individual duration of response over time * To assess progression-free survival in this patient population * To assess overall survival in this patient population EXPLORATORY OBJECTIVES * To assess PD-L1 as a predictive marker for response to pembrolizumab